{
    "code": "22000014",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=22000014",
    "time": "2023-03-17 03:39:30",
    "許可證字號": "衛署罕菌疫輸字第000014號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/08\/27",
    "發證日期": "101\/08\/27",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA02200001409",
    "中文品名": "泰吉利濃縮靜脈輸注液 300 毫克",
    "英文品名": "Tysabri concentrate for solution for infusion 300mg",
    "適應症": "單一藥物治療反覆發作型多發性硬化症，其病人群為下列成人病人：\r\n1) 已使用至少一種改善病程進展的治療 (Disease-modifying therapy, DMT)，但是仍持續惡化的病人，或 \r\n2) 病情急速惡化的反覆發作型多發性硬化症病人。",
    "劑型": "270注射劑",
    "包裝": "15毫升小瓶",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "Natalizumab",
    "限制項目": "02輸　入 1D須執行風險管理計畫",
    "申請商名稱": "0407901100  衛采製藥股份有限公司",
    "申請商地址": "台北市長安東路一段十八號九樓",
    "主製造廠": [
        {
            "製造廠名稱": "FDE0559000  VETTER PHARMA-FERTIGUNG GMBH &amp; CO KG",
            "製造廠廠址": "MOOSWIESEN 2, 88214 RAVENSBURG, GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FDK0070000  FUJIFILM DIOSYNTH BIOTECHNOLOGIES DENMARK APS",
            "製造廠廠址": "BIOTEK ALLE 1, HILLEROD, 3400, DENMARK",
            "製造廠公司地址": "",
            "製造廠國別": "DENMARK",
            "製程": "原料藥製造廠及包裝廠"
        },
        {
            "製造廠名稱": "FNL0116000  BIOGEN NETHERLANDS B.V.",
            "製造廠廠址": "PRINS MAURITSLAAN 13, 1171 LP BADHOEVEDORP, THE NETHERLANDS",
            "製造廠公司地址": "",
            "製造廠國別": "NETHERLANDS",
            "製程": "許可證持有者"
        },
        {
            "製造廠名稱": "FUS0785000  BIOGEN INC.",
            "製造廠廠址": "5000 DAVIS DRIVE, RESEARCH TRIANGLE PARK, NORTH CAROLINA 27709, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "主成分(drug substance)製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013003400",
            "成分名稱": "Natalizumab",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Tysabri vial with Taiwan label_1-108-03-28(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "Tysabri 標籤-110-10-20.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=013&Type=8"
        },
        {
            "title": "Tysabri 外盒-110-10-20.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=012&Type=8"
        }
    ]
}